Altre lingue Tango Therapeutics, Inc.

Azioni

TNGX

US87583X1090

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 06/03/2026			Variaz. 5gg	Var. 1 gen.
16,95 ^USD	+0,71%		+52,15%	+91,31%

06/03	Tango Therapeutics annuncia la concessione di incentivi ai sensi della Nasdaq Listing Rule 5635(c)(4)	RE
06/03	Tango Therapeutics, Inc.: prospettiva positiva di Wedbush	ZM

Altre lingue

06/03	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03	Tango Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)
06/03	Tango Therapeutics : Corporate Presentation
05/03	Galapagos Nv Announces Executive and Management Changes, Effective March 4, 2026
05/03	Top Midday Gainers
05/03	Tango Therapeutics Shares Rise After Q4 Loss Narrows
05/03	Erasca and Tango Therapeutics Enter into Clinical Collaboration Agreement
05/03	Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
05/03	Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy
05/03	Tango Therapeutics Q4 Loss Narrows
05/03	Earnings Flash (TNGX) Tango Therapeutics Posts Q4 Loss $0.29 a Share
05/03	Erasca and Tango Therapeutics enter into clinical collaboration to evaluate combination of ERAS-0015 and vopimetostat
05/03	Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
20/02	BB Biotech bestätigt Gewinn 2025
18/02	Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
03/02	Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
14/01	Tango Therapeutics : Corporate Presentation
08/01	Tango Therapeutics, Inc. Announces Board and Executive Changes
08/01	Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026
08/01	Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall
08/01	Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor
08/01	Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
05/01	Tango Therapeutics, Inc. Appoints Sung Lee to its Board of Directors
05/01	Tango Therapeutics Appoints Sung Lee to Board of Directors
23/12	Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025.